CIBIT/ICNAS participate in the AIMS-2-TRIALS
CIBIT/ICNAS will participate in the AIMS-2-TRIALS (Autism Innovative Medicine Studies-2-Trials). It began in June 2018 and will run until May 2023. This is a collaboration with 48 partners from 14 countries!
UC will participate in the validation of stratification biomarkers particularly in participant recruitment and testing for the LEAP Epilepsy study. UC will take part in the clinical network development and sustainability and testing of new medicines, in particular as a clinical centre for the serotonin and GABA studies. We will also contribute to project’s data management and analysis with expertise in clinical neuroscience, positron emission topography (PET) and magnetic resonance imaging (MRI).